Abstract
Much of our knowledge about HIV infection has been obtained from cohort studies, including description of the natural history of infection, identification of CD4 count and viral load as good surrogate markers of clinical progression, identification of co-factors [including older age and viral infections (CMV, HCV)] for progression of HIV-related disease and assessment of impact of highly active antiretroviral therapy on clinical outcomes. The Cologne–Bonn cohort was founded by Gerd Fätkenheuer and Bernd Salzberger after introduction of combination antiretroviral therapy in 1996 and has delivered important findings which have helped to improve treatment strategies as well as quality of overall care in HIV infection in these two cities. Indeed, the first pivotal paper from the cohort reported on an unexpectedly high rate of virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients. The subsequent analysis of risk factors for virological failure initiated the development of more potent HIV combination therapy. This review summarizes some of the major findings and contributions from the Cologne–Bonn cohort since 1996.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Gottlieb MS, Schanker HM, Fan PT, et al. Pneumocystis Pneumonia−Los Angeles. MMWR Weekly. 1981;30(21):250–2.
Gottlieb MS, Schroff R, Schanker HM, et al. Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: evidence of a new acquired cellular immunodeficiency. N Engl J Med. 1981;305:1425–31.
Barre-Sinoussi F, Chermann JC, Rey F, et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for AIDS. Science. 1983;220:868–71.
Fätkenheuer G, Theisen A, Rockstroh J, et al. Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients. AIDS. 1997;11(14):F113–6.
Kempf DJ, Marsh KC, Kumar G, et al. Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir. Antimicrob Agents Chemother. 1997;41(3):654–60.
Rockstroh JK, Bergmann F, Wiesel W, et al. Efficacy and safety of twice daily first-line ritonavir/indinavir plus double nucleoside combination therapy in HIV-infected individuals. German Ritonavir/Indinavir Study Group AIDS. 2000;14(9):1181–5.
Lichterfeld M, Nischalke HD, Bergmann F, et al. Long-term efficacy and safety of ritonavir/indinavir at 400/400 mg twice a day in combination with two nucleoside reverse transcriptase inhibitors as first line antiretroviral therapy. HIV Med. 2002;3(1):37–43.
Collaboration Antiretroviral Therapy Cohort, Zwahlen M, Harris R, May M, et al. Mortality of HIV-infected patients starting potent antiretroviral therapy: comparison with the general population in nine industrialized countries. Int J Epidemiol. 2009;38(6):1624–33.
Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord, Lewden C, Bouteloup V, De Wit S, et al. All-cause mortality in treated HIV-infected adults with CD4 ≥ 500/mm3 compared with the general population: evidence from a large European observational cohort collaboration. Int J Epidemiol. 2012;41(2):433–45.
Ehren K, Hertenstein C, Kümmerle T, et al. Causes of death in HIV-infected patients from the Cologne–Bonn cohort. Infection. 2014;42(1):135–40.
Smith CJ, Ryom L, Weber R, et al. D:a:D Study Group. Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration. Lancet. 2014;384(9939):241–8.
Engsig FN, Zangerle R, Katsarou O, et al. Antiretroviral Therapy Cohort Collaboration (ART-CC) and the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in Euro Coord. Long-term mortality in HIV-positive individuals virally suppressed for > 3 years with incomplete CD4 recovery. Clin Infect Dis. 2014;58(9):1312–21.
Platten M, Linnemann R, Kümmerle T, et al. Clinical course and quality of care in ART-naïve patients newly presenting in a HIV outpatient clinic. Infection. 2014;42(5):849–57.
Mocroft A, Lundgren JD, Sabin ML, Monforte A, Brockmeyer N, Casabona J, et al. Risk factors and outcomes for late presentation for HIV-positive persons in Europe: results from the collaboration of observational HIV epidemiological research Europe study (COHERE). PLoS Med. 2013;10(9):e1001510.
Ingle SM, May MT, Gill MJ, et al. Antiretroviral Therapy Cohort Collaboration. Impact of risk factors for specific causes of death in the first and subsequent years of antiretroviral therapy among HIV-infected patients. Clin Infect Dis. 2014;59(2):287–97.
Acknowledgments
This work was supported by the DZIF TTU HIV Project 05.803 and the German Center for Infection Research (DZIF).
Conflict of interest
JKR received honoraria for speaking at educational events or consulting from Abbvie, Bionor, BMS, Boehringer, Gilead, Janssen, Merck, Tibotec and ViiV.
